Español (pdf)
Articulo en XML
Referencias del artículo
Traducción automática
Enviar articulo por email
Citado por SciELO 
Similares en
SciELO 
uBio 
Permalink
Revista Arbitrada Interdisciplinaria de Ciencias de la Salud. Salud y Vida
versión On-line ISSN 2610-8038
Resumen
MOROCHO-SAQUINAULA, Ángel Mauricio; ALBORNOZ-ZAMORA, Elsa Josefina y DONOSO-NORONA, Riber Fabián. Anticoagulation in patients with severe SARS-CoV-2 pneumonia in ICU. Salud y Vida [online]. 2025, vol.9, n.esp1, pp.626-633. Epub 30-Oct-2025. ISSN 2610-8038. https://doi.org/10.35381/s.v.v9i1.4709.
Objective:
To determine anticoagulation in patients with severe SARS-CoV-2 pneumonia admitted to intensive care unit.
Method:
Literature review of evidence on anticoagulants in COVID-19 patients in ICU. Database search in PubMed, Cochrane, Scielo, Science Direct and Scopus under MeSH terms. Analytical studies, clinical trials and systematic reviews from 2022 were included.
Results:
From 157 initial studies, after applying inclusion and exclusion criteria, 13 investigations were analyzed. Critical COVID-19 patients present cumulative incidence of thrombotic complications of 25% at 7 days and 48% at 14 days. Low molecular weight heparin at therapeutic doses reduces mortality especially in patients with elevated D-dimer.
Conclusions:
Both prophylactic and therapeutic anticoagulation reduces thrombotic complications, but high hemorrhagic risk exists requiring individualized treatment.
Palabras clave : Anticoagulation; SARS-CoV-2; intensive care units; thromboembolism..
